UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Allscripts Healthcare Solutions

In a report published Monday, Sterne Agee Group reiterated its Buy rating on Allscripts Healthcare Solutions MDRX, and raised its price target from $13.50 to $15.00. Sterne Agee noted, “Our analysis suggests a $15-19 valuation range for MDRX shares should a go-private transaction be consummated by year-end. At the low end, this valuation range is 20% above today's closing price, while the top end implies 50% upside. As such, we have raised our price target to $15 per share from $13.50.” Allscripts Healthcare Solutions closed on Friday at $12.42.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsSterne Agee Group
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!